COMPASS, a double-blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II.
- Resource Type
- Article
- Source
Molecular Genetics & Metabolism . Feb2023, Vol. 138 Issue 2, pN.PAG-N.PAG. 1p.- Subject
- *
ENZYME replacement therapy
*SAFETY - Language
- ISSN
- 1096-7192